logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Cyclooxygenase Inhibitor class drugs

    FiltersReset Filters
    7 results

    • ketorolac tromethamine

      (ketorolac tromethamine)
      SOLA Pharmaceuticals, LLC
      Usage: Ketorolac tromethamine ophthalmic solution is indicated for the temporary relief of ocular itching caused by seasonal allergic conjunctivitis and for treating postoperative inflammation in patients who have undergone cataract extraction.

    • ketorolac tromethamine

      (KETOROLAC TROMETHAMINE)
      Hospira, Inc.
      Usage: Ketorolac tromethamine is indicated for the short-term management (≤5 days) of moderately severe acute pain, typically in postoperative settings. It should start with intravenous or intramuscular dosing, with oral use only for continuation if necessary. The combined use is limited to 5 days to minimize adverse reactions.

    • ketorolac tromethamine

      (ketorolac tromethamine)
      Sandoz Inc
      Usage: Ketorolac tromethamine ophthalmic solution is indicated for temporary relief of ocular itching from seasonal allergic conjunctivitis and for treating postoperative inflammation following cataract extraction.

    • ketorolac tromethamine

      (Ketorolac Tromethamine)
      Chartwell RX, LLC
      Usage: Ketorolac tromethamine tablets are indicated for the short-term management (≤ 5 days) of moderately severe acute pain requiring opioid-level analgesia, primarily in postoperative settings. They serve as continuation therapy after initial IV or IM administration. Use should be minimized to reduce the risk of adverse reactions.

    • ketorolac tromethamine

      (Ketorolac Tromethamine)
      SOLA Pharmaceuticals, LLC
      Usage: Ketorolac tromethamine is indicated for short-term management (≤5 days) of moderately severe acute pain, typically in postoperative settings. It should be initiated intravenously or intramuscularly, with oral use only for continuation. Duration should not exceed 5 days to mitigate adverse reactions.

    • omidria

      (phenylephrine and ketorolac)
      Rayner Surgical Inc.
      Usage: Omidria® is used during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis and to reduce postoperative ocular pain.

    • sprix

      (ketorolac tromethamine)
      Zyla Life Sciences US LLC
      Usage: SPRIX is indicated for the short-term management (up to 5 days) of moderate to moderately severe pain in adults requiring opioid-level analgesia. It is not intended for use in pediatric patients under 2 years of age.